This comprehensive comparative analysis examined the economic and health care resource utilization implications of initiating glucocorticoid and exon-skipping therapy for Duchenne muscular dystrophy (DMD).
Higher health care costs and utilization rates were seen among patients living with Duchenne muscular dystrophy (DMD) who were treated with exon-skipping therapy compared with patients who received branded or generic glucocorticoid treatment or no treatment, according to the results of a comprehensive comparative analysis presented at AMCP Nexus 2023.
Investigators evaluated health care costs and health care resource utilization (HCRU) among 4 groups of patients, stratified by treatment and before/after treatment periods: those receiving exon-skipping therapy (n = 43); those receiving glucocorticoids, branded (n = 172) or generic (n = 149); and a control group not on DMD therapy (n = 68). Data for July 1, 2018, through January 31, 2022 came from the Merative MarketScan Commercial claims database, and data for July 1, 2018, through December 31, 2020, came from Medicaid claims. They noted a lack of research on the economic implications and HCRU rates of glucocorticoid and exon skipping therapy as their reason for initiating this investigation. The index date was either the day a patient began DMD treatment or the diagnosis date if not on treatment.
Patient age ranged from 13 to 19 years, 81.08% of patients reported a White ethnicity (n = 180/222) and 9.46 (n = 21/222) a Black ethnicity, and most had insurance through Medicaid (71.06%).
In the pre-index period, mean (SD) total all-cause office visits were highest in the exon-skipping group at 9.27 (10.41), followed by 6.9 (6.4) in the generic glucocorticoid group, 4.4 (6.4) in the no-treatment group, and 0.3 (8.8) in the branded glucocorticoid group. Corresponding all-cause outpatients visits were 108.1 (134.7), 96.7 (150.9), 102.2 (134.4), and 78.2 (106.6). All-cause emergency department (ED) also were highest in the exon-skipping therapy group and lowest in the no-treatment group, at 0.8 (2.1) vs 0.2 (0.9), respectively. However, the average all-cause length of stay (LOS) was longest in the generic glucocorticoid group, at 4.2 (27.3) and lowest in the branded group, at 0.2 (1.9).
In the postindex period, the following results were seen:
Annual pharmacy spend was exponentially higher in the exon-skipping therapy group in both the pre- and postindex periods, at $10,843 and $648,869, respectively, compared with the following, which the investigators said equated to a 60-fold increase:
Higher, too, were annualized medical expenditures among the exon-skipping therapy group in the pre- and postindex periods, respectively:
Overall, mean annual outpatient costs grew 3-fold in the exon-skipping therapy group, which the study authors attribute to potential use of the treatment in an outpatient setting, whereas those for the remaining patient groups had “only minimal increases,” they noted.
“The study found that the exon-skipping therapy group incurred higher costs and HCRU compared with both the branded and generic glucocorticoid therapy subgroups,” the authors concluded, “as well the subgroup without any DMD treatments, in both the pre- and postindex periods.”
Reference
Scavini M, Posner N, Dorling P, Talaga A, Kane AS, Alvir J. The economic impact of treatment initiation in Duchenne muscular dystrophy: a retrospective US claims analysis. Presented at: AMCP Nexus 2023; AMCP Nexus 2023; October 16-October 19, 2023; Orlando, Florida.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More